1. Home
  2. Browse
  3. HRA008462
HRA008462
   HRA008462.xlsx
Title:
Neoadjuvant Aumolertinib for Inoperable Stage III EGFR-Mutant Non-Small Cell Lung Cancer
Release date:
2025-03-12
Description:
This phase II trial evaluated neoadjuvant Aumolertinib, a third-generation EGFR-TKI, for inoperable stage III EGFR-mutant NSCLC. Among 51 patients treated, the objective response rate was 70.6%, with 45.1% converting to operable disease and undergoing successful R0 resection. Five patients had major pathological responses, and three had complete responses. RNA-sequencing revealed increased CD8+ T-cell infiltration post-treatment, particularly in tumors with Ex19-Del mutations. Aumolertinib demonstrated promising efficacy, a high surgical conversion rate, and a tolerable safety profile.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA013411
Study type:
Disease Study
Disease name:
NSCLC
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC002005
DAC name:
Targeted therapy of NSCLC
Contact person:
Zhang Peng
Email:
zhangpeng1121@tongji.edu.cn
Description:
Targeted therapy has improved the treatment non-small cell lung cancer (NSCLC) with driver gene mutations. However, most patients will develop drug resistance after therapy. Here, we combined bulk, single cell and spatial transcriptomics to identify the spatial landscape of the NSCLC tumor microenvironment (TME) during targeted therapy. Multidimensional bioinformatics analyses revealed distinct transcriptomic heterogeneity of the TME. Our study provides novel insights into the complex ecosystem of NSCLC and offers clues for combinational therapies to overcome drug resistance.
Individuals & samples
Files
Request Data
Submitter:   Zhang Peng / zhangpeng1121@tongji.edu.cn
Organization:   Shanghai Pulmonary Hospital Tongji University
Submission date:   2024-08-18
Requests:   1